MAIP: A Prediction Platform for Predicting Blood-Stage Malaria Inhibitors

Nicolas Bosc (nbosc@ebi.ac.uk)
European Bioinformatics Institute https://orcid.org/0000-0003-3562-1328

Eloy Felix
European Bioinformatics Institute https://orcid.org/0000-0002-5512-6810

Ricardo Arcila
European Bioinformatics Institute https://orcid.org/0000-0002-8253-7375

David Mendez
European Bioinformatics Institute https://orcid.org/0000-0002-0294-5484

Martin Saunders
GlaxoSmithKline https://orcid.org/0000-0001-9642-2600

Darren Green
GlaxoSmithKline https://orcid.org/0000-0001-9063-2754

Jason Ochoada
Saint Jude Children's Research Hospital Department of Chemical Biology and Therapeutics https://orcid.org/0000-0003-0728-8820

Anang Shelat
Saint Jude Children's Research Hospital Department of Chemical Biology and Therapeutics https://orcid.org/0000-0002-6266-2910

Eric Martin
Novartis Institutes for BioMedical Research https://orcid.org/0000-0001-7040-5108

Preeti Iyer
AstraZeneca https://orcid.org/0000-0003-0136-0123

Ola Engkvist
AstraZeneca https://orcid.org/0000-0003-4970-6461

Andreas Verras
Schrodinger Inc. https://orcid.org/0000-0001-5353-4784

James Duffy
Medicines for Malaria Ventures Discovery https://orcid.org/0000-0002-9447-8982

Jeremy Burrows
Medicines for Malaria Ventures Discovery https://orcid.org/0000-0001-8448-6068

Mark Gardner
AMG Consultants Ltd https://orcid.org/0000-0002-9322-1181

Andrew Leach
Research article

**Keywords:** Malaria, antimalarial drug discovery, QSAR, classification modelling, open source software, naïve Bayes, machine learning, data fusion

**DOI:** https://doi.org/10.21203/rs.3.rs-41814/v1

**License:** ☕️ 📧 This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Malaria is a disease affecting hundreds of millions of people across the world, mainly in developing countries and especially in Sub-Saharan Africa. It is the cause of hundreds of thousands of deaths each year and there is an ever-present need to identify and develop effective new therapies to tackle the disease and overcome increasing drug resistance. Here, we extend a previous study in which a number of partners collaborated to develop a consensus in silico model that can be used to identify novel molecules that may have antimalarial properties. The performance of machine learning methods generally improves with the number of data points available for training. One practical challenge in building large training sets is that the data is often proprietary and cannot be straightforwardly integrated. Here, this was addressed by sharing QSAR models, each built on a private data set. We describe the development of an open-source software platform for creating such models, a comprehensive evaluation of methods to create a single consensus model and a web platform called MAIP available at https://www.ebi.ac.uk/chembl/maip/. MAIP is freely available for the wider community to make large-scale predictions of potential malaria inhibiting compounds. This project also highlights some of the practical challenges in reproducing published computational methods and the opportunities that open source software can offer to the community.

Introduction

Despite substantial scientific progress, new, affordable and safe malaria medicines are urgently required to overcome increasing resistance against artemisinin-based combination therapies (ACTs), treat vulnerable populations, interrupt the parasite life cycle by blocking transmission to the vectors, prevent infection and target malaria species that transiently remain dormant in the liver. Malaria remains one of the most serious infectious diseases; it threatens nearly half of the world’s population and led to over 400,000 deaths in 2019, predominantly among children in resource-limited areas in Africa, Asia and Central and South America [1].

Clinicians, researchers and, most importantly, patients remain acutely aware of the limitations of the current antimalarial medicines. These include drug resistance, lack of a single dose cure and suboptimal therapies for children and pregnant women. Drug resistance remains a constant threat and patients with resistance to the front-line ACTs are now being routinely identified in Southeast Asia [2]. Secondly, all existing malaria treatments require patient adherence to the course of treatment. A single exposure medicine would allow health workers to directly control and observe drug administration ensuring completion of the treatment course and help to avoid parasite exposure to sub-therapeutic doses [3]. Finally, to protect the entire population, new medicines suitable for use in mothers and babies are urgently needed. Such medicines need age and weight appropriate dosing, child friendly formulation and comprehensive reproductive toxicology evaluation to ensure they are safe to use during pregnancy [4].
The past two decades have seen not only the development of highly efficient high-throughput screening platforms but also significant collaborative efforts between the commercial, not-for-profit and academic communities to join forces in tackling the malaria challenge, often by screening in-house compound libraries and making some of the results available in the literature [5–7]. Whilst precise assay details vary, many of these screens involve cell-based assays that can test for compounds that inhibit the asexual blood cell stage of *Plasmodium spp.* infection, which is the cause of symptomatic malaria. Red blood cells are the site of exponential parasite replication to potentially \(> 10^{12}\) parasites per patient, in the case of *Plasmodium falciparum*, and all disease symptoms are caused by the response to the repeated lysis and invasion of erythrocytes by the asexual blood stage parasites. Drug discovery projects starting from the hits arising from these screening experiments have led to the identification of candidates that have been progressed to clinical development. In addition, chemogenomic methods have enabled the discovery of new drug targets and mechanism of action from the same pool of compounds [8, 9].

Machine learning is a computational tool widely-used in drug discovery [10, 11], with its origins in Quantitative Structure-Activity Relationship (QSAR) modelling. Virtual screening is one of the key practical applications of such computational models, enabling large numbers of compounds (including as-yet-unsynthesised molecules) to be assessed for their therapeutic potential prior to experiment [12]. Such machine learning models have the greatest general applicability when trained on large and chemically diverse chemical collections. A practical challenge is that the datasets available for training such models are limited by data availability. Whilst large-scale, open access databases such as ChEMBL [13] have made a significant impact, nevertheless much bioactivity data is proprietary, making integration a significant challenge due to confidentiality concerns.

Previously, a consortium of Pharma and not-for-profit organisations described a consensus machine learning approach to predict blood stage malaria inhibition [14]. The approach taken involved, first, each partner training a model following the same protocol based on their own in-house data. The models were then shared within the consortium without revealing the confidential information contained in the underlying chemical entities. Proprietary datasets were further obscured by only sharing descriptor weights for the subset of descriptors important in the individual models. A consensus approach, combining several models, showed improved predictivity performance compared to the individual models. The method was subsequently evaluated by selecting and then screening a set of compounds, resulting in a 3-fold enrichment. However, for a number of practical reasons, including the dependence on commercial software, the project was terminated at this stage, and critically, a prediction platform freely available for wider use was not delivered.

Here, we report a successor project, using open source tools and additional datasets, that has resulted in a freely available and accessible combined model for the community to use in developing new malaria treatments. One of our initial goals was to replicate as closely as possible the original study, whilst using different, open source software. In addition to the creation of the open access tool based on a larger dataset, our current study therefore also explores the important, and rarely considered, question of method reimplementation and reproducibility in machine learning for drug discovery [15, 16]. Even with
the greater availability of public datasets, there can be dozens if not hundreds of settings that may be required to reimplement the exact same model. Our study may therefore also guide future efforts with regard to what is feasible in this context.

Herein, we report a panel of models trained on blood stage malaria inhibition data from several independent partners using open source tools. We explore different ways to combine these models in order to achieve enhanced prediction performance. We compare our results with those obtained previously using a variety of measures. We describe our choice of consensus approach that has been implemented in an online prediction platform now freely available for community use.

**Methods**

Training datasets

Eleven datasets from five different partners were used in this study to train models. The Evotec, Johns Hopkins, MRCT, MMV - St. Jude, AZ, GSK, and St. Jude Vendor Library datasets were essentially the same as described previously [14]. The Medicines for Malaria Venture (MMV) partner provided three additional datasets to be used for training models (MMV5, MMV6, MMV7; see Table 1) and the Novartis dataset was significantly different from the original work; these four new or modified datasets are therefore described in detail, as follows:

**Novartis.** The Novartis data set contains 3,355,412 measurements covering 2,726,063 unique canonical smiles assayed in a high-throughput screen using erythrocytes infected with the 3D7 Plasmodium falciparum (PF) strain. The activity cut-off was INH ≥ 50% at either 1.25 or 12.5 µM compound concentration. Of these, 107,505 always measured as active, 2,593,470 always measured as inactive, and 25,088 were measured ambiguously as both active and inactive. Each measurement was treated as a separate observation in the modelling. The data are proprietary to Novartis and were used to build Novartis models.

**MMV5.** MMV purchased 446,465 compounds that were screened using 3D7 PF strain with Sybr Green dye at 3 µM concentration with an endpoint at 72 h. For the purposes of building a model, compounds were classed as active if they demonstrated an EC50 value < 10uM or if they showed a mean percentage inhibition at 3uM ≥ 50%. On that basis, 4,980 compounds were classified as active and 441,485 as inactive. The data are proprietary to MMV and were used to construct MMV5 models.

**MMV6.** MMV purchased 249,444 compounds that were tested using Dd2 PF strain at a concentration of 12.5 mM with a SybrGreen readout. Approximately 8,000 screening actives were selected on the criteria that % inhibition ≥ 80%. Then the compounds were clustered and the list reduced to 2,123 compounds that were tested in dose-response on Dd2-SybrGreen with 10 mM top concentration. For the purposes of building a model, compounds tested in the dose-response assay were classed as active if they achieved an EC50 ≤ 10 mM (533 compounds), inactive if not. Of the remainder, compounds were classed as active if their mean percentage inhibition value at 12.5 mM was ≥ 80% (inactive if not). This gave a total of
6,328 active and 243,116 inactive compounds for model building. The data are proprietary to MMV and were used to construct MMV6 models.

**MMV7.** MMV purchased 12,732 compounds that were tested at 12.5 µM against Dd2 PF strain using a Sybr Green endpoint at 72 h. 1,073 screening actives were selected based on the criteria that % inhibition \( \geq 70\% \) in each of 2 replicates. From these, 590 compounds gave a dose-response value < 10 µM. For the purposes of model construction, compounds were considered active if they had an IC50 < 10 µM or if they showed a mean percentage inhibition value of \( > 80\% \). This resulted in 848 active and 11,884 inactive compounds. The data are proprietary to MMV and were used to construct MMV7 models.

**Validation datasets**

Three datasets were used for model validation purposes, henceforth referred to as the MMV test set, the PubChem dataset and the St. Jude Screening Set (see Table 1). The latter was already used for model validation in the earlier work but with a single difference due to a compound class change [14].

**MMV test set.** The MMV test set was the outcome of the previous study [14], where the generated consensus model obtained by combining all the partners’ models was used to predict the activity of a collection of 12 million compound extracted from the eMolecules database of commercially available compounds. Compounds with a model consensus score in the −20 to 0 interval were excluded from further consideration. Substructure search filtering was performed to remove well known anti-malaria chemotypes. Only lead-like compounds were selected by using molecular properties, removing potential Pan-assay interference compounds (PAINS) and manual curation. After a clustering step based on the compound molecular fingerprints, 5,869 compounds were tested using PF Dd2 train at 12.5 µM in a blood stage malaria assay by monitoring DNA dye at an MMV Network Test Center. Those with an activity > 50% were considered as ‘active’ and leading to a total of 1,198 active and 4,671 inactive compounds. A resulting 3-fold enrichment for the compounds predicted as active relative to the ones predicted as active by the model was observed.

**PubChem.** This dataset was obtained combining the results from two assays in PubChem [17].

AID1159554 is a primary screen measuring PF Dd2 strain growth inhibition using SYBR green I in human erythrocytes. 94,441 unique substances were screened at 10 µM and their activity or inactivity status was assigned by PubChem. AID1159566 is a confirmatory screen where 468 substances identified from the primary screen were screened a second time at different concentrations for an EC50 to be determined by regression analysis. Activity and inactivity were also determined directly by PubChem. We combined the results of these assays and considered as active the compounds that were flagged as being ‘active’ in both assays. From this selection, compounds identified as active at a single concentration dose but not validated in the dose-response assay were discarded. Finally, for this validation set 384 compounds were considered as active and the remaining 91,412 were considered inactive.
### Table 1
Statistics for the datasets used in this study

| Dataset origin           | model name      | dataset size | number of actives | number of inactives | ratio of active to inactive compounds |
|--------------------------|-----------------|--------------|-------------------|---------------------|---------------------------------------|
| AZ                       | AZ              | 11,574       | 3,272             | 8,302               | 0.3941                                |
| GSK                      | GSK             | 2,006,390    | 13,535            | 1,992,855           | 0.0068                                |
| Evotec                   | MMV1            | 229,429      | 339               | 229,090             | 0.0015                                |
| Johns Hopkins            | MMV2            | 2,524        | 247               | 2,277               | 0.1085                                |
| MRCT                     | MMV3            | 40,059       | 235               | 39,824              | 0.0059                                |
| MMV - St. Jude           | MMV4            | 305,810      | 2,507             | 303,303             | 0.0083                                |
| MMV5                     | MMV5            | 446,465      | 4,980             | 441,485             | 0.0113                                |
| MMV6                     | MMV6            | 249,444      | 6,328             | 243,116             | 0.0260                                |
| MMV7                     | MMV7            | 12,732       | 848               | 11,884              | 0.0714                                |
| Novartis                 | Novartis        | 2,700,975    | 107,505           | 2,593,470           | 0.0415                                |
| St. Jude Vendor Library  | StJudeVendor    | 541,403      | 2,026             | 539,377             | 0.0038                                |
| St. Jude Screening Set   | Validation set  | 220,691      | 9,082             | 211,609             | 0.0429                                |
| MMV test set             | Validation set  | 5,869        | 1198              | 4671                | 0.2565                                |
| PubChem                  | Validation set  | 91,796       | 384               | 91,412              | 0.0042                                |

Molecule Standardisation, Descriptor calculation and model-building

The previous study [14] used proprietary methods available via Pipeline Pilot for molecule standardisation, calculation of molecular descriptors and building computational models [18]. For this work we focussed entirely on open source tools; this would also make it possible for other potential partners to contribute models in the future without limitation.

**Molecule preparation.** Each molecule was standardised using an open source python-rdkit standardiser [19]. Molecules that failed the standardisation were removed. Descriptors were calculated using RDKit [20]. Six different combinations of descriptors were explored for each dataset (see Table 2).
Table 2
Model descriptor combination for each partner model.

| Descriptors | ECFP | FCFP | logP | MW | RTB | HBA | HBD | HAC |
|-------------|------|------|------|----|-----|-----|-----|-----|
| model1      | X    |      |      |    |     |     |     |     |
| model2      |      | X    |      |    |     |     |     |     |
| model3      | X    | X    | X    | X  | X   | X   | X   | X   |
| model4      | X    |      | X    | X  | X   | X   | X   | X   |
| model5      |      | X    | X    | X  | X   | X   | X   | X   |
| model6      | X    | X    |      | X  | X   | X   | X   | X   |

ECFP: unhashed RDKit Morgan fingerprint with radius of 3, useFeatures parameter set to False and useCounts set to True; FCFP: unhashed RDKit Morgan fingerprint with radius of 3, useFeatures parameter set to True and useCounts set to True; logP: molecular lipophilicity \[21\]; MW: molecular weight; RTB: number of rotatable bounds; HBA: number of hydrogen bound acceptor; HBD: number of hydrogen bound donor; HAC: Heavy atom count.

The non-binary descriptors (logP, MW, RTB, HBA, HBD and HAC) were discretised into 10 bins. Unhashed ECFP and FCFP fingerprints were used, so the numbers of bit descriptors varied according to size and chemical diversity of each individual dataset. The resulting data were stored in sparse matrix objects for more efficient processing.

**Model building.** A Naïve Bayes approach was used for model building, to ensure consistency with the previous study \[14\]. This is in general a robust approach for creating models using binary molecular descriptors. We implemented the algorithm described in \[22, 23\] using the BaseDiscreteNB base class in scikit-learn, to ensure that the model was compatible with all the utilities in the scikit-learn library \[24\].

In this model, the posterior probability for each feature \(F_i\) is defined by (1):

\[
P(\text{active} \mid F_i) = \frac{(A_{F_i}+1)}{(T_{F_i}(A/T)+1)} \quad \#\ (1)
\]

Where \(A\) is the number of active molecules in the set, \(T\) the total number of molecules in the set, \(T_{F_i}\) the total number of molecules that contain feature \(F_i\) and \(A_{F_i}\) number of active molecules that contain feature \(F_i\).

Variable selection was used to remove uninformative descriptors, defined as those with \(\text{abs}(\log[P(\text{active} \mid F_i)]) < 0.05\).

Finally, the score for a given compound as calculated by the model is defined by (2):

\[
P_{\text{active}} = \log[P(\text{active} \mid F1)] + \log[P(\text{active} \mid F2)] + \ldots + \log[P(\text{active} \mid Fn)] \quad \#\ (2)
\]

**Metrics**
**ROC AUC score.** The receiver operator characteristic (ROC) curve is calculated by plotting the fraction of false positives on the x-axis and the fraction of true positives on the y-axis. The area under the curve (AUC) provides a measure of how well a model is able to classify binary data. A value 0.5 corresponds to selecting compounds at random while a perfect model will return a ROC AUC value of 1. This metric is often used to measure the performance of classification models as it is insensitive to class imbalance.

**Enrichment factor.** The enrichment factor (EF) is the hit rate (the proportion of active compounds) within a defined sorted fraction divided by the total hit rate [25]. It is defined by (3):

\[
EF[X] = \frac{P[X]}{N[X]} \cdot \frac{N}{P} \# (3)
\]

Where \(X\) is the user-defined fraction, \(P[X]\) the number of actives in the fraction, \(N[X]\) the total number of compounds in the fraction, \(P\) the total number of actives and \(N\) the total number of compounds. The EF is frequently used as a pragmatic measure of performance, reflecting the common use of in silico models to identify a subset of compounds for experimental evaluation. In this work, we calculated this metric at 1% and 10%, respectively.

**Fingerprint coverage.** The fingerprint coverage compares the set of bit descriptors retained by the Naïve Bayes model with the set of bits derived from the compound fingerprint. Hence, it is calculated as the proportion of bits present in the molecule that are shared with the model [14].

**Software development, model building and sharing**

A Dockerfile repository was used to provide a secure and transparent way of distributing the software, containing a json configuration file with the different sets of descriptors for training and the MMV test set for calculating performance metrics. A Python script calculates the molecular descriptors, removes uninformative variables, trains the models and generates performance reports. Two different performance reports are generated; one from a 5-fold cross validation with random splits and the second by training the model on the whole training set and validating it against the MMV test set.

Each partner ran the docker image after having formatted their datasets to fit the platform's input format and returned to EMBL-EBI all trained models and model performance reports through appropriate secure channels. Models were created in a human readable format, so each partner was also able to verify that no structural or other confidential information was included.

**Data visualisation using t-distributed Stochastic Neighbor Embedding**

t-distributed Stochastic Neighbor Embedding (t-SNE) is an algorithm performing a nonlinear dimensionality reduction and designed for data visualisation [26]. The chemical space for the three validation sets was derived from the t-SNE calculation using the same fingerprint descriptors as for model 2 (Table 2). The resulting sparse matrix corresponding to the chemical features present in the
validation set compounds was used as input for scikit-learn's implementation of the t-SNE algorithm using a perplexity value of 500 [24].

**Results**

Validation of model-building protocols

Our first goal was to assess the ability of our new software methods and code to reproduce the previous study [14]. We determined that the major difference would be due to implementations of the descriptor calculations as the distributions of calculated physico-chemical properties are reasonably well (but not perfectly) correlated (Additional file 1). To explore the impact of differences in fingerprint implementations on model-building and performance we used the MMV – St. Jude dataset with only FCFP6 fingerprints and RDKit Morgan fingerprints with radius of 3 and features from Pipeline Pilot and RDKit, respectively. After removing the uninformative bits, we built two Naïve Bayes models and predicted the MMV test set. A pairwise comparison using the Pearson correlation coefficient (R) for the two sets of scores gave a value of 0.88, indicating a good but not perfect correlation (Additional file 2A). In a second comparison, we used ECFP6 fingerprints and RDKit Morgan fingerprints with radius of 3 but without features. This gave an R coefficient of 0.98, indicating almost perfect identity between the two model implementations (Additional file 2B).

These results are not unexpected and are due to differences in the way that which ECFP and FCFP fingerprints are calculated. Both are circular fingerprints, describing the environment in the vicinity of each atom in the molecule. ECFP captures the atom-based substructural information while FCFP represents function-based substructural information [27]. Differences in feature definitions between Pipeline Pilot and RDKit explain the lower correspondence between models built using these two approaches, whilst the ECFP implementations are almost identical.

Nevertheless, the results did confirm to our satisfaction that it would be possible to deliver model performance that was very close to those of the previous study.

Model comparison

**Internal validation.** The performance for each dataset across the 6 different descriptor combinations is shown in Fig. 1. Somewhat surprisingly, the 5-fold cross validations show that the choice of descriptors appears to have rather limited impact on the performance. Indeed, we observed little variability between the six descriptor sets. Moreover, combining physico-chemical descriptors and molecular fingerprints results in barely any effect (comparing model 1, 3 and 4, and model 2, 5, 6, respectively).

**Figure 1:** Results of the internal validation for the 6 models trained by each partner dataset. The error bars represent the standard deviation returned by the 5-fold cross validation.

**External validation.** External model performance was evaluated using the MMV test set (Fig. 2). We observed relatively little difference between all the models. When comparing different combinations of
descriptors, we observed little variation, though FCFP alone (model 2) is generally better than ECFP alone (model 1).

As the various models were so similar in performance, we pragmatically decided to use the same set of descriptors for each dataset and opted for model2 (FCFP fingerprints only). Using a single set of descriptors makes the prediction of new compounds more straightforward and faster to compute.

_Figure 2: Results of the external validation for the 6 models trained by each partner dataset. This validation was performed predicting the MMV test set._

Consensus approaches

Several consensus options were investigated to identify the optimal approach for inclusion in the public model. We describe here in detail two of the approaches explored, MaxScore and metamodel.

**MaxScore.** For any given combination of models, the MaxScore prediction for a test compound is the maximum score predicted by any one of the component models. With 11 different models there are a total of 2,047 possible combinations, each containing from 1 to 11 individual models. All 2,047 combinations were generated and evaluated using three criteria: ROC AUC score, EF[1%] and EF[10%]. EF[1%] and EF[10%] represent practical virtual screening scenarios where a small fraction is selected from a pool of compounds. We show in Fig. 3 the impact of increasing the number of models in the MaxScore consensus, using these three metrics for the three validation sets.

_Figure 3: Median performance of the consensus approaches for the MMV (blue), PubChem (red) and St. Jude Screening set (green) validation sets. The error bars represent the standard deviations. The x-axis represents how many models were combined to calculate the MaxScore. For direct comparison, the performance of the metamodel has been added on the right end side of the plots. The performance was assessed by means of (A) the ROC AUC score, (B) EF[1%] and (C) EF[10%]._

Across the three validation sets, we observe significant variance in the performance of individual models; in some cases these outperform the all-model consensus. This is an expected result and it is dependent upon the validation dataset. Also, modest improvements in performance are obtained as more models are included in the consensus for ROC and EF[10%]. Small consensus models worked best for the EF[1%] metric for the PubChem and St. Jude Screening sets. The all-model MaxScore consensus delivers a performance at least equivalent to the median performance of other consensus models with fewer contributing models. We also note that enrichment factor performance correlates with the numbers of compounds in the validation sets, with MMV and St. Jude Screening containing the least and most populated ones. The three validation sets also differ on other aspects. The MMV and St. Jude Screening sets are the results of single-dose assays, while the PubChem active compounds were determined in a dose-response assay. Moreover, the MMV test set is already more enriched with antimalarial compounds than the other validation sets, and was specifically designed in the previous project. This might partly explain its relatively lower enrichment values.
**Metamodel.** In this approach, we merged all the different partner models into a single model based on a combined set of fingerprints bits, where the weight for any one bit is given by summing the weights for that bit across the different individual models. The resulting metamodel is a Naïve Bayes model that generates scores from 893,855 binary variables. It has the key advantage of providing a consensus score from a single model, thus providing significant run-time advantages when compared to the all-model consensus which would require each new compound to be first scored by 11 different models. The metamodel approach is compared with the all-model MaxScore consensus in Table 3 and is also annotated on Fig. 3.

In Table 3 we also present summary results for two other consensus approaches that were investigated. The mean score (MeanScore) is calculated as the arithmetic average of the prediction scores returned by the individual models. The MinRank algorithm scores a compound as the minimum rank across all models. Overall, we could not identify a clear winner when comparing the results across these three validation sets.

| consensus     | performance metrics | MMV test set | PubChem | St. Jude Screening Set |
|---------------|---------------------|--------------|---------|------------------------|
| MaxScore      | ROC AUC score       | 0.70         | 0.77    | 0.79                   |
| metamodel     |                     | 0.67         | 0.69    | 0.82                   |
| MeanScore     |                     | 0.71         | 0.78    | 0.80                   |
| MinRank       |                     | 0.64         | 0.77    | 0.73                   |
| MaxScore      | EF[1%]              | 2.9          | 7.0     | 13.3                   |
| metamodel     |                     | 3.3          | 7.3     | 10.9                   |
| MeanScore     |                     | 2.8          | 12.8    | 16.8                   |
| MinRank       |                     | 2.5          | 7.0     | 11.0                   |
| MaxScore      | EF[10%]             | 2.4          | 3.0     | 4.6                    |
| metamodel     |                     | 2.1          | 2.4     | 4.9                    |
| MeanScore     |                     | 2.3          | 3.0     | 4.3                    |
| MinRank       |                     | 1.7          | 3.0     | 3.6                    |

**Chemical space analysis**

In machine learning a standard way to assess the chemical space over which the model can generate reliable predictions is by defining its domain of applicability [28–30]. It is usually calculated from the variables used to describe the model training set. Methods such as conformal prediction are furthermore
able to quantify the prediction certainty [31–33]. Our consensus approaches were developed with the underlying training sets remaining obscured, leaving us with limited options to perform further analysis and in particular it was not possible to directly assess the model's domain of applicability. Nevertheless, to confirm the predictivity of our methods, we comprehensively assessed their performance using three validation sets as described above. Additionally, we further investigated the variation in performance across these different sets by considering fingerprint coverage. For a given molecule the fingerprint coverage is calculated as the proportion of bits shared with the model and so is a measure of the similarity of the compound with the model. Taking the MaxScore consensus as an example, for each compound in the three validation sets, fingerprint coverage values were calculated as the mean across the 11 models and we compared the resulting metric with the corresponding consensus score, distinguishing active from inactive compounds. See Fig. 4, where active compounds are dark and inactive compounds are light. The MMV and the St. Jude datasets show similar distributions, with high compound score for these sets appearing to require high fingerprint coverage. This might be considered expected behaviour since the score is the sum of feature log(probabilities) (see Methods). However, it is not the case that high fingerprint coverage necessarily leads to a high score. Indeed, the metric does not consider the weight of these shared bits, and it is possible that they contribute very little to final score, if not negatively. Having only a few bits shared with the model would be expected to lead to lower scores as there are just too few contributing bits. The results for the PubChem dataset differ from the two others, showing a much weaker relationship between score and the mean fingerprint coverage. Interestingly, the lowest fingerprint coverage values in this dataset have higher absolute values than for the other two sets, whilst also having a narrower range of scores.

*Figure 4: Comparison between fingerprint coverage and prediction score for (A) MMV, (B) PubChem and (C) St. Jude Screening sets, where active compounds are dark and inactive compounds are light.*

To further explore this, Fig. 5 shows the results of a t-distributed Stochastic Neighbor Embedding (t-SNE) visualisation of all validation set compounds. Described above, this nonlinear dimensionality reduction technique is particularly useful for preserving local data structures [34, 35]. We observe in Fig. 5 that the MMV test set and St. Jude Screening set compounds are more similar between each other than they are compared to the PubChem dataset compounds, respectively. One possible explanation for these results is that the PubChem set is inherently less diverse, being based around a small number of central scaffolds, than the other two sets. However, such analysis is beyond the scope of this study. We should also be cautious in over-interpreting these results. In particular, the fingerprint coverage metric relies only on the bits shared with the model, ignoring bits in the model but not in the molecule. Hence, while it gives an indication on how much of the compound bits are in the model, it completely eludes the information present in the model but not in the compound. This is analogous to the observations of Martin et al. [36] and Hempel's “raven paradox”.

*Figure 5: t-SNE visualisation of the three validation set chemical spaces.*

Web application
The above results demonstrate that the metamodel shows comparable results to the other consensus approaches in our validation experiments. Furthermore, there are significant computational advantages in having to deal with just a single model instead of eleven from a system performance perspective. We have therefore implemented the metamodel in a web application called MAIP (MAlaria Inhibitor Prediction), which is available for the community to make malaria activity predictions.

MAIP is accessible through https://www.ebi.ac.uk/chembl/maip/ (Fig. 6A). Users upload a file containing their molecules represented by SMILES strings and associated identifiers. Once submitted, a job is queued for execution on the EMBL-EBI compute infrastructure (Fig. 6B). Each submitted molecule is standardised as described above, FCFP descriptors are calculated and the molecule is then scored using the metamodel. A file containing individual compound scores can be downloaded when the job finishes. To facilitate analysis of the results, a bar chart giving the score distribution is generated together with summary information on the three validation sets to assist users in any subsequent compound selections. Documentation on the project and MAIP are available at: https://chembl.gitbook.io/malaria-project/

Figure 6: A. Frontend of the MAIP platform, accessible at https://www.ebi.ac.uk/chembl/maip/; B. MAIP system architecture.

MAIP is intended to be used as a prioritisation tool, offering users a way to identify compounds of interest for further analysis and selection. MAIP does not directly return a prediction flag, e.g. ‘predicted antimalarial compound’; users should scrutinise their results before making any decisions on next steps. To assist this, documentation is provided with the results together with relevant statistics for our three validation sets (Fig. 7). For each dataset, the higher the model score, the greater the observed enrichment. Further, the thresholds needed to pick 1%, 10% and 50% of the predictions correlate with the dataset size. These data can be used to guide the users in their analysis.

Users are also strongly advised to use additional in silico filters to assess the suitability of any virtual hits from MAIP prior to any experimental testing. High scoring compounds may have physicochemical properties and/or substructure features that are unsuitable as starting points for a malaria (or indeed any) drug discovery programme. In addition, some of the training sets used in MAIP contain examples of known anti-malarial compounds (e.g. aminoquinolines). Thus, molecules that score highly in MAIP may have already been worked on extensively in anti-malarial programmes. Public bioactivity resources such as ChEMBL can be used to determine whether the anti-malarial activity is already known for specific structural classes [13]. As part of MMV’s commitment to Open Innovation, screening slots in the MMV Plasmodium falciparum asexual blood stage assay are being made available to test 3rd party compounds identified using MAIP. Please contact MMV (maip@mmv.org) for more details.

Figure 7: Screenshot from MAIP document page (https://chembl.gitbook.io/malaria-project/using-maip-results#result-summary ) showing the model validation results. For each validation set, the numbers of active and inactive compounds are indicated. The scores used to measure the enrichment factors are indicated between parentheses.
Discussion and Conclusions

The key output from this work is a practical tool that we hope will be of value in the global search for new malaria treatments. We have built upon and extended a previous study, delivering a computational model derived from > 6.5 million malaria bioactivity values. We believe that this is the largest collection of malaria data assembled to date and the largest public machine learning model for a drug discovery target. We have created a comprehensive open source software capability for molecule standardisation and model building, based on the widely used RDKit library, that will enable other groups to build their own models and potentially to extend our current model by the inclusion of additional malaria bioassay data. This software was used to deliver 11 separate \textit{in silico} models that individually show heterogeneous performance across the three different validation sets employed. We anticipate (though without direct access to the underlying structures we cannot be completely certain) that this is due to the different chemical space covered by each individual dataset. Combining the models in a consensus approach gives improved and more robust performance. Of particular note is that the metamodel approach to combining Naive Bayes models was shown to deliver good performance across multiple validation sets and also has the key advantage of computational efficiency. This model has been implemented in an easy-to-use web application. Although the compounds used in the training sets remain accessible only to their owners, the wider community can nevertheless take advantage of their malaria bioactivity properties without breaching confidentialities.

MAIP was developed with the objective to be relatively easy to maintain promoting sustainability of the tool. Combined with the open source software used to develop the model, this will enable both existing and new partners to further contribute to the consensus model. In addition, the modular nature of the MAIP system means that the same approach could be easily applied to other areas, for example with alternative machine learning algorithms and/or to other areas of drug discovery. The scientific community is now invited to use our platform in the hope that this may lead to the initiation of new antimalarial drug discovery projects.

\textbf{Abbreviations}

AUC
Area under the curve
ECFP
Extended Connectivity Fingerprint
EF
Enrichment factor
FCFP
Functional-Class Fingerprints
HAC
Heavy atom count
HBA
number of hydrogen bound acceptor
HBD
number of hydrogen bound donor
logP
molecular lipophilicity
MW
molecular weight
PAINS
Pan-assay interference compounds
PF
Plasmodium Falciparum
QSAR
Quantitative Structure-Activity Relationship
RTB
number of rotatable bounds
t-SNE
t-distributed Stochastic Neighbor Embedding

**Declarations**

**Availability of data and materials**

The code to standardise the compounds and train the models is available on GitHub:

- standardiser: [https://github.com/flatkinson/standardiser](https://github.com/flatkinson/standardiser).
- ModifiedNB: [https://github.com/chembl/ModifiedNB](https://github.com/chembl/ModifiedNB).
- mmv_train_image: [https://github.com/chembl/mmv_train_image](https://github.com/chembl/mmv_train_image)

The ready to use Docker image to generate the models is available at [https://hub.docker.com/r/chemblgroup/mmv_train](https://hub.docker.com/r/chemblgroup/mmv_train)

The MAIP platform is available at [https://www.ebi.ac.uk/chembl/maip/](https://www.ebi.ac.uk/chembl/maip/)

**Competing interests**

The authors declare that they have no competing interests.

**Funding**
The research leading to these results has received funding from (1) the Bill & Melinda Gates Foundation, (2) Member States of the European Molecular Biology Laboratory (EMBL).

Authors' contributions

NB, EF, EJM, DVSG, MRS, AAS, JO, OE and PI contributed to the modelling work. AV, DVSG, AAS and JB contributed to the original work and paper that inspired this project. NB, EF, ARL, JD, JB and JMFG contributed to the project design. EF, RA and DM developed the MAIP system. NB, EF and ARL wrote the manuscript. All authors accepted the final manuscript.

Acknowledgements

The authors would like to acknowledge AstraZeneca, GSK, MMV, Novartis and St Jude Children's Research Hospital for letting us use their data to train and test models. We thank the Bill & Melinda Gates Foundation for funding and Rich Elliot for his valuable input to discussions concerning the project. Thanks also to Francis Atkinson for developing the compound standardiser used in this project.

References

1. WHO (2019) World malaria report 2019
2. Blasco B, Leroy D, Fidock DA (2017) Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat Med 23:917–928. https://doi.org/10.1038/nm.4381
3. Bruxvoort K, Goodman C, Kachur SP, Schellenberg D (2014) How Patients Take Malaria Treatment: A Systematic Review of the Literature on Adherence to Antimalarial Drugs. PLoS ONE 9:e84555. https://doi.org/10.1371/journal.pone.0084555
4. Dellicour S, Tatem AJ, Guerra CA et al (2010) Quantifying the Number of Pregnancies at Risk of Malaria in 2007: A Demographic Study. PLoS Medicine 7:e1000221. https://doi.org/10.1371/journal.pmed.1000221
5. 10.1073/pnas.0802982105
   Plouffe D, Brinker A, McNamara C et al (2008) In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proceedings of the National Academy of Sciences 105:9059–9064. https://doi.org/10.1073/pnas.0802982105
6. Gamo F-J, Sanz LM, Vidal J et al (2010) Thousands of chemical starting points for antimalarial lead identification. Nature 465:305–310. https://doi.org/10.1038/nature09107
7. Guiguemde WA, Shelat AA, Bouck D et al (2010) Chemical genetics of Plasmodium falciparum. Nature 465:311–315. https://doi.org/10.1038/nature09099
8. Phillips MA, Burrows JN, Manyando C et al (2017) Malaria. Nature Reviews Disease Primers 3:17050. https://doi.org/10.1038/nrdp.2017.50
9. LaMonte GM, Rocamora F, Marapana DS et al (2020) Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway. Nat Commun 11:. https://doi.org/10.1038/s41467-020-15440-4

10. Cumming JG, Davis AM, Muresan S et al (2013) Chemical predictive modelling to improve compound quality. Nat Rev Drug Discovery 12:948–962. https://doi.org/10.1038/nrd4128

11. Vamathevan J, Clark D, Czdrowski P et al (2019) Applications of machine learning in drug discovery and development. Nat Rev Drug Discovery 18:463–477. https://doi.org/10.1038/s41573-019-0024-5

12. Cherkasov A, Muratov EN, Fourches D et al (2014) QSAR Modeling: Where Have You Been? Where Are You Going To? J Med Chem 57:4977–5010. https://doi.org/10.1021/jm4004285

13. Mendez D, Gaulton A, Bento AP et al (2019) ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res 47:D930–D940. https://doi.org/10.1093/nar/gky1075

14. Verras A, Waller CL, Gedeck P et al (2017) Shared Consensus Machine Learning Models for Predicting Blood Stage Malaria Inhibition. J Chem Inf Model 57:445–453. https://doi.org/10.1021/acs.jcim.6b00572

15. Patel M, Chilton ML, Sartini A et al (2018) Assessment and Reproducibility of Quantitative Structure–Activity Relationship Models by the Nonexpert. J Chem Inf Model 58:673–682. https://doi.org/10.1021/acs.jcim.7b00523

16. Haibe-Kains B, Adam GA, Hosny A et al (2020) The importance of transparency and reproducibility in artificial intelligence research. arXiv 2003.00898

17. Kim S, Chen J, Chen T et al (2019) PubChem 2019 update: improved access to chemical data. Nucleic Acids Res 47:D1102–D1109. https://doi.org/10.1093/nar/gky1033

18. Dassault Systèmes BIOVIA, Pipeline, Pilot (2016) 2017.2.0.1361. Dassault Systèmes, San Diego

19. Atkinson F (2020) standardiser. GitHub

20. RDKit: Open-Source Cheminformatics. http://www.rdkit.org

21. Wildman SA, Crippen GM (1999) Prediction of Physicochemical Parameters by Atomic Contributions. J Chem Inf Comput Sci 39:868–873. https://doi.org/10.1021/ci990307l

22. Nidhi, Glick M, Davies JW, Jenkins JL (2006) Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases. J Chem Inf Model 46:1124–1133. https://doi.org/10.1021/ci060003g

23. Xia X, Maliski EG, Gallant P, Rogers D (2004) Classification of Kinase Inhibitors Using a Bayesian Model. J Med Chem 47:4463–4470. https://doi.org/10.1021/jm0303195

24. Pedregosa F, Varoquaux G, Gramfort A et al (2011) Scikit-learn: Machine Learning in Python. Journal of Machine Learning Research 12:2825–2830

25. Truchon J-F, Bayly CI (2007) Evaluating Virtual Screening Methods: Good and Bad Metrics for the “Early Recognition” Problem. J Chem Inf Model 47:488–508. https://doi.org/10.1021/ci600426e

26. van der Matten L, Hinton G (2008) Visualizing data using t-SNE. J Mach Learn Res 9:2579–2605
27. Rogers D, Hahn M (2010) Extended-Connectivity Fingerprints. J Chem Inf Model 50:742–754. https://doi.org/10.1021/ci100050t

28. Weaver S, Gleeson MP (2008) The importance of the domain of applicability in QSAR modeling. J Mol Graph Model 26:1315–1326. https://doi.org/10.1016/j.jmgm.2008.01.002

29. Sahigara F, Mansouri K, Ballabio D et al (2012) Comparison of different approaches to define the applicability domain of QSAR models. Molecules 17:4791–4810. https://doi.org/10.3390/molecules17054791

30. Sheridan RP (2012) Three Useful Dimensions for Domain Applicability in QSAR Models Using Random Forest. J Chem Inf Model 52:814–823. https://doi.org/10.1021/ci300004n

31. Norinder U, Carlsson L, Boyer S, Eklund M (2014) Introducing Conformal Prediction in Predictive Modeling. A Transparent and Flexible Alternative to Applicability Domain Determination. J Chem Inf Model 54:1596–1603. https://doi.org/10.1021/ci5001168

32. Bosc N, Atkinson F, Felix E et al (2019) Large scale comparison of QSAR and conformal prediction methods and their applications in drug discovery. J Cheminform 11:4. https://doi.org/10.1186/s13321-018-0325-4

33. Cortés-Ciriano I, Bender A (2019) Concepts and Applications of Conformal Prediction in Computational Drug Discovery. arXiv:190803569 [cs, q-bio]

34. Janssen APA, Grimm SH, Wijdeven RHM et al (2019) Drug Discovery Maps, a Machine Learning Model That Visualizes and Predicts Kinome–Inhibitor Interaction Landscapes. J Chem Inf Model 59:1221–1229. https://doi.org/10.1021/acs.jcim.8b00640

35. Karlov DS, Sosnin S, Tetko IV, Fedorov MV (2019) Chemical space exploration guided by deep neural networks. RSC Advances 9:5151–5157. https://doi.org/10.1039/C8RA10182E

36. Martin E, Cao E (2015) Euclidean chemical spaces from molecular fingerprints: Hamming distance and Hempel's ravens. J Comput Aided Mol Des 29:387–395. https://doi.org/10.1007/s10822-014-9819-y

**Figures**
Figure 1

Results of the internal validation for the 6 models trained by each partner dataset. The error bars represent the standard deviation returned by the 5-fold cross validation.
Figure 2

Results of the external validation for the 6 models trained by each partner dataset. This validation was performed predicting the MMV test set.
C. number of models in the consensus

Figure 3

Results of the external validation for the 6 models trained by each partner dataset. This validation was performed predicting the MMV test set.
Figure 4
Comparison between fingerprint coverage and prediction score for (A) MMV, (B) PubChem and (C) St. Jude Screening sets, where active compounds are dark and inactive compounds are light.

Figure 5

t-SNE visualisation of the three validation set chemical spaces.
The malaria inhibition prediction (MAIP) platform is the result of a public-private collaboration whose aim is to develop a consensus model for predicting blood stage malaria inhibition. Five Pharma and not-for-profit partners trained a model using code developed by EMBL-EBI on three private datasets. The resulting models were combined by EMBL-EBI and made available through this public prediction platform.

More information and details on the term and result format files are given here.

One of our partners, the Medicines for Malaria Venture (MMV), is committed to supporting open innovation and taking drug discovery to the next level. Please contact us if you would like to test a sample of any compounds that you identify using MAIP in MMV’s Plasmodium falciparum asexual blood stage assay. Terms and conditions are available on the MMV website.

A.

B. EMBL-EBI
Figure 6

A. Frontend of the MAIP platform, accessible at https://www.ebi.ac.uk/chembl/maip/; B. MAIP system architecture.

**Result summary**

| Performance metrics         | ROC AUC score | EF[1%] | EF[10%] | EF[50%] | #actives | #inactives |
|-----------------------------|---------------|--------|---------|---------|----------|------------|
| St. Jude Screening Set      | 0.81          | 12.1 (71) | 4.8 (36) | 1.8 (15) | 9,082    | 211,609    |
| MMV test set                | 0.67          | 3.5 (60)  | 2.1 (41) | 1.4 (23) | 1,198    | 4,671      |
| Pubchem                     | 0.69          | 7.0 (56)  | 2.8 (47) | 1.5 (34) | 384      | 91,412     |

Figure 7

Screenshot from MAIP document page (https://chembl.gitbook.io/malaria-project/using-maip-results#result-summary) showing the model validation results. For each validation set, the numbers of active and inactive compounds are indicated. The scores used to measure the enrichment factors are indicated between parentheses.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile2.docx
- Additionalfile1.xlsx